Percutaneous Coronary Interventions Using a Ridaforolimus?Eluting Stent in Patients at High Bleeding Risk
Journal of the American Heart Association
JANUARY 12, 2024
Drug‐eluting stents have been shown to be superior to bare‐metal stents in patients with HBR, even when patients were given abbreviated periods of dual antiplatelet therapy (DAPT). Short DAPT has not been evaluated with the EluNIR ridaforolimus‐eluting stent.
Let's personalize your content